EGFR associated expression profiles vary with breast tumor subtype
暂无分享,去创建一个
Charles M Perou | Melissa A Troester | Katherine A Hoadley | Lisa A Carey | Xiaping He | C. Fan | C. Perou | K. Hoadley | Xiaping He | P. Bernard | L. Carey | V. Weigman | M. Troester | L. Sawyer | C. Sartor | Cheng Fan | Philip S Bernard | Victor J Weigman | Thais Rieger-House | Lynda R Sawyer | Carolyn I Sartor | Thais Rieger-House | Carolyn I. Sartor
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[3] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[4] G. Tortora,et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] C. Gridelli,et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer , 2006, British Journal of Cancer.
[6] R. Mass. The HER receptor family: a rich target for therapeutic development. , 2004, International journal of radiation oncology, biology, physics.
[7] S. Cassenaer,et al. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice , 2001, Oncogene.
[8] I. Bedrosian. The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer , 2005 .
[9] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[10] Douglas A. Hosack,et al. Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.
[11] L. Bégin,et al. The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.
[12] A. Giordano,et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. , 2005, Frontiers in bioscience : a journal and virtual library.
[13] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[14] Q. She,et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[16] M. Dowsett,et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[18] R. Nicholson,et al. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth , 2006, Breast Cancer Research and Treatment.
[19] J. Kononen,et al. Cyclin E overexpression and amplification in human tumours , 2003, The Journal of pathology.
[20] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[21] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[22] C. Perou,et al. Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.
[23] H. Gogas,et al. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group , 2005, Breast Cancer Research and Treatment.
[24] J. McCubrey,et al. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). , 2003, International journal of oncology.
[25] R. Medema,et al. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.
[26] P. Brown,et al. DNA arrays for analysis of gene expression. , 1999, Methods in enzymology.
[27] J. Baselga. Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.
[28] L. Bégin,et al. Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.
[29] C. Perou,et al. Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines , 2022 .
[30] M. Fukuoka,et al. Molecular target-based cancer therapy: tyrosine kinase inhibitors , 2003, International Journal of Clinical Oncology.
[31] R. Jove,et al. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. , 1997, Cancer research.
[32] G. Viglietto,et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib , 2006, Journal of cellular physiology.
[33] C. Perou,et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. , 2005, The Journal of clinical investigation.
[34] G. Giaccone,et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. , 2006, International journal of cancer.
[35] E. Venkatraman,et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.
[36] D. Lev,et al. Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells , 2004, British Journal of Cancer.
[37] E. Tokunaga,et al. Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients , 2006, International journal of cancer.
[38] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[39] J. C. Wilkinson,et al. The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* , 2005, Journal of Biological Chemistry.
[40] M. Ellis,et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[42] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[43] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] P. Johnston,et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.
[45] G. Tortora,et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] W. Bretz,et al. Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.
[47] Jinsong Liu,et al. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. , 2005, Biochemical and biophysical research communications.
[48] M. Hambek,et al. Reduction of cisplatin dosage by ZD 1839. , 2005, Anticancer research.
[49] R. Schiff,et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] A. Hollestelle,et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.
[51] P. Fasching,et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer , 2004, Breast Cancer Research and Treatment.
[52] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[53] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[54] F. Chen,et al. The Small Heat Shock Protein αB-Crystallin Negatively Regulates Cytochrome c- and Caspase-8-dependent Activation of Caspase-3 by Inhibiting Its Autoproteolytic Maturation* , 2001, The Journal of Biological Chemistry.
[55] Peter Kirkpatrick,et al. Erlotinib hydrochloride , 2005, Nature Reviews Drug Discovery.
[56] G. Mills,et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.
[57] R. Weichselbaum,et al. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.
[58] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[59] Zhiyuan Hu,et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Simak Ali,et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. , 2005, The Lancet. Oncology.
[61] 中尾 光輝,et al. KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .
[62] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[63] G. Gasparini,et al. Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] J. Foekens,et al. Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients , 2006, Clinical Cancer Research.
[65] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[66] J. Robertson,et al. Overview of tyrosine kinase inhibitors in clinical breast cancer. , 2005, Endocrine-related cancer.
[67] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[68] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[69] Zhiyuan Hu,et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay , 2006, Breast Cancer Research.
[70] R. Harris,et al. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. , 2005, Cellular signalling.
[71] Terry L. Smith,et al. Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.
[72] Daniel Birnbaum,et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.
[73] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[74] C. Boland,et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells , 2003, British Journal of Cancer.
[75] C. Osborne,et al. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[76] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[77] J. Darbon,et al. The p42/p44 Mitogen-activated Protein Kinase Activation Triggers p27Kip1 Degradation Independently of CDK2/Cyclin E in NIH 3T3 Cells* , 2001, The Journal of Biological Chemistry.
[78] C. Perou,et al. High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays. , 2005, BioTechniques.